Home > Insider Trading > Filing (0001179110-17-013874)

Filing Details

Accession Number:: 0001179110-17-013874
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-08 16:21:21
Reporting Period:: 2017-11-06

Accepted Time:: 2017-11-08 16:21:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597264	Blueprint Medicines Corp	BPMC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1638474	W. Jeffrey Albers	C/O Blueprint Medicines Corporation 38 Sidney Street, Suite 200 Cambridge MA 02139	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-11-06	24,514	$1.87	30,000	No	4	M	Direct
Common Stock	Disposition	2017-11-06	400	$73.89	29,600	No	4	S	Direct
Common Stock	Disposition	2017-11-06	1,999	$72.91	27,601	No	4	S	Direct
Common Stock	Disposition	2017-11-06	2,600	$71.67	25,001	No	4	S	Direct
Common Stock	Disposition	2017-11-06	7,432	$70.40	17,569	No	4	S	Direct
Common Stock	Disposition	2017-11-06	16,469	$69.74	1,100	No	4	S	Direct
Common Stock	Disposition	2017-11-06	1,100	$68.95	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2017-11-06	24,514	$0.00	24,514	$1.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
825,034		2024-07-30	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.46 to $74.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.65 to $73.35 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.23 to $72.13 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.13 to $71.12 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.13 to $70.12 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.65 to $69.10 per share.
This option was granted on July 30, 2014. This option vested as follows: (i) 12,620 shares vested in two installments at a rate of 6,310 shares on December 21, 2015 and May 21, 2016; (ii) 35,871 shares vested in three installments at a rate of 11,957 on June 21, 2016, July 21, 2016 and August 21, 2016; and (iii) 4,983 shares vested on September 21, 2016.